SYM FINANCIAL Corp Reduces Stock Position in Pfizer Inc. (NYSE:PFE)

SYM FINANCIAL Corp trimmed its position in Pfizer Inc. (NYSE:PFE) by 14.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,952 shares of the biopharmaceutical company’s stock after selling 1,170 shares during the quarter. SYM FINANCIAL Corp’s holdings in Pfizer were worth $201,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. City Holding Co. raised its stake in shares of Pfizer by 18.9% during the 2nd quarter. City Holding Co. now owns 29,910 shares of the biopharmaceutical company’s stock valued at $837,000 after buying an additional 4,744 shares during the last quarter. Accel Wealth Management boosted its position in Pfizer by 12.6% in the 2nd quarter. Accel Wealth Management now owns 8,317 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 932 shares in the last quarter. Sax Wealth Advisors LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $300,000. Central Valley Advisors LLC purchased a new position in shares of Pfizer during the 2nd quarter valued at approximately $95,000. Finally, Optimum Investment Advisors lifted its stake in shares of Pfizer by 88.4% in the 2nd quarter. Optimum Investment Advisors now owns 21,214 shares of the biopharmaceutical company’s stock valued at $594,000 after purchasing an additional 9,956 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Wolfe Research began coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $32.92.

Pfizer Stock Performance

NYSE:PFE opened at $25.72 on Friday. The company’s 50-day moving average is $27.54 and its two-hundred day moving average is $28.40. The firm has a market capitalization of $145.75 billion, a price-to-earnings ratio of 34.76, a PEG ratio of 0.69 and a beta of 0.65. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.17) earnings per share. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 8th were given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.53%. The ex-dividend date was Friday, November 8th. Pfizer’s payout ratio is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.